Drawing for ELEV8BIO

USPTO serial 88317403

ELEV8BIO

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
STIGLITZ, SUSAN R
Law office
TMEG LAW OFFICE 109 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with ELEV8BIO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Alexander JL Theoharis

ALEXANDER JL THEOHARIS THE APEX LAW GROUP LLP200 FIRST AVE. W., SUITE 104SEATTLE, WA 98119UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
035Investor development and management in the nature of business intermediary services relating to the matching of potential private investors with entrepreneurs needing funding; Business development services, namely, marketing strategy development and implementation of strategy plans; Personnel management services in the nature of advisory board development and management; Regulatory compliance development and management in the nature of regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodiesACTIVESep 1, 2017
042Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Biochemical research and development; Conducting clinical trials for others; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific research, namely, conducting clinical trials for others; Medical research services in the field of cancer; Pharmaceutical research and development; Providing a web site featuring technology enabling physicians to access resources in clinical medicine; Providing a website featuring educational information in the field of clinical research; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical testing services and information in the field of cancer research and disease classification; Scientific research and development; Scientific and technological services, namely, research and design in the field of integrated system architecture that allows for the rapid development of highly interactive and customizable learning applications; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of Cancer and Acute and Chronic Devastating Diseases and Conditions beyond Cancer; Stem cell research services; Testing, inspection, research, or development of pharmaceutical preparations for gene therapyACTIVESep 1, 2017

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Nov 18, 2019MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Nov 18, 2019ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
May 7, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 7, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 7, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 7, 2019DOCKASSIGNED TO EXAMINER—
Mar 18, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 1, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance